MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
Why Is MEI Pharma Stock Soaring On Friday?
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma to Consider Strategic Alternatives
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
National Bank of Canada FI Takes $36,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
MEI Pharma Recommends Stockholders Not to Consent
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions
MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
MEI Pharma Announces Results of Special Meeting of Stockholders
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
MEI Pharma Postpones Special Meeting of Shareholders
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights